New indication in pediatric patients, including term neonates for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) Injection
PR Newswire —
PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ -- Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Elucirem™ (gadopiclenol) injection. The new...